Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 (Encaleret) in Autosomal Dominant Hypocalcemia (ADH) Type 1

Trial Profile

A Phase 2b, Open-label Dose-ranging Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics, and Efficacy of CLTX-305 (Encaleret) in Autosomal Dominant Hypocalcemia (ADH) Type 1

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Encaleret (Primary)
  • Indications Hypocalcaemia; Hypoparathyroidism
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors BridgeBio Pharma; Calcilytix therapeutics

Most Recent Events

  • 13 Nov 2023 Status changed from active, no longer recruiting to completed.
  • 10 Oct 2023 Results presented in the bridgebio pharma Media Release.
  • 10 Oct 2023 According to a BridgeBio Pharma media release, the Company plans additional presentations related to the program at the upcoming American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top